Peloton Therapeutics

pelotontherapeutics.com

Peloton Therapeutics, Inc. is an oncology drug discovery and development company focused on advancing first-in-class small molecule therapies that provide patients suffering from life-threatening diseases with new therapeutic options.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

INNOTECH AND OSARO COLLABORATE TO BUILD A DEMONSTRATION AI PICKING ROBOT SYSTEM FOR ROHTO PHARMACEUTICAL’S NEXT-GENERATION SMART FACTORY

INNOTECH and OSARO | January 12, 2022

news image

OSARO Inc. a global leader in the development and provision of advanced robotics automation, and INNOTECH CORPORATION, which provides advanced products for electronics and consumer industries, have announced a collaboration to create an innovative demonstration for Rohto Pharmaceutical Co., Ltd. using AI piece-picking robots. The two companies are jointly providing picking robots and jointly building a system for their introduction into a new factory production line, scheduled for completion in ...

Read More

PHARMACY MARKET, PHARMA TECH

MTTI OBTAINS FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG (IND) FOR HÜRTHLE CELL THYROID CANCER

Molecular Targeting Technologies, Inc | December 09, 2022

news image

Molecular Targeting Technologies, Inc. a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the allowance of an Investigational New Drug application by the U.S. Food and Drug Administration. It is now waiting for Institutional Review Board approval. Once approved by IRB, it will enable a Phase I/II clinical study of the Safety, Dosimetry and Efficacy of EBTATE in adult patients with metastatic, radioactive iodine non-responsive Hürthle...

Read More

Pharmacy Market

EVEREST MEDICINES ANNOUNCES COMMERCIAL LAUNCH AND FIRST PRESCRIPTION FOR XERAVA® IN CHINA

PRNewswire | July 27, 2023

news image

Everest Medicines a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today XERAVA® (eravacycline) has been successfully launched in China with its first prescription issued at Huashan Hospital affiliated to Fudan University. The commercialization of XERAVA® in China marks Everest's transformation into a commercial-stage innovative biopharmaceutical company. XERAVA® is the wor...

Read More

Pharmacy Market

SONIVIE RECEIVES IDE APPROVAL FROM FDA FOR ITS PILOT STUDY TO TREAT HYPERTENSION WITH ITS RENAL ARTERY DENERVATION TIVUS™ TECHNOLOGY

SoniVie | June 20, 2022

news image

SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound System to treat a variety of hypertensive disorders, announced that on May 5th 2022 the U.S. Food and Drug Administration granted IDE approval for its "REDUCED1" Pilot study to treat Resistant Hypertension Patients with Renal Artery Denervation using TIVUS™, its innovative Ultra-Sound Ablation System. Resistant hypertension is defined as blood pressure higher than...

Read More
news image

Business Insights

INNOTECH AND OSARO COLLABORATE TO BUILD A DEMONSTRATION AI PICKING ROBOT SYSTEM FOR ROHTO PHARMACEUTICAL’S NEXT-GENERATION SMART FACTORY

INNOTECH and OSARO | January 12, 2022

OSARO Inc. a global leader in the development and provision of advanced robotics automation, and INNOTECH CORPORATION, which provides advanced products for electronics and consumer industries, have announced a collaboration to create an innovative demonstration for Rohto Pharmaceutical Co., Ltd. using AI piece-picking robots. The two companies are jointly providing picking robots and jointly building a system for their introduction into a new factory production line, scheduled for completion in ...

Read More
news image

PHARMACY MARKET, PHARMA TECH

MTTI OBTAINS FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG (IND) FOR HÜRTHLE CELL THYROID CANCER

Molecular Targeting Technologies, Inc | December 09, 2022

Molecular Targeting Technologies, Inc. a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the allowance of an Investigational New Drug application by the U.S. Food and Drug Administration. It is now waiting for Institutional Review Board approval. Once approved by IRB, it will enable a Phase I/II clinical study of the Safety, Dosimetry and Efficacy of EBTATE in adult patients with metastatic, radioactive iodine non-responsive Hürthle...

Read More
news image

Pharmacy Market

EVEREST MEDICINES ANNOUNCES COMMERCIAL LAUNCH AND FIRST PRESCRIPTION FOR XERAVA® IN CHINA

PRNewswire | July 27, 2023

Everest Medicines a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today XERAVA® (eravacycline) has been successfully launched in China with its first prescription issued at Huashan Hospital affiliated to Fudan University. The commercialization of XERAVA® in China marks Everest's transformation into a commercial-stage innovative biopharmaceutical company. XERAVA® is the wor...

Read More
news image

Pharmacy Market

SONIVIE RECEIVES IDE APPROVAL FROM FDA FOR ITS PILOT STUDY TO TREAT HYPERTENSION WITH ITS RENAL ARTERY DENERVATION TIVUS™ TECHNOLOGY

SoniVie | June 20, 2022

SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound System to treat a variety of hypertensive disorders, announced that on May 5th 2022 the U.S. Food and Drug Administration granted IDE approval for its "REDUCED1" Pilot study to treat Resistant Hypertension Patients with Renal Artery Denervation using TIVUS™, its innovative Ultra-Sound Ablation System. Resistant hypertension is defined as blood pressure higher than...

Read More

Resources

resource image

Pharma Tech

ValGenesis e-Logbook

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us